Study tests if starting stronger drugs earlier tames psoriatic arthritis

NCT ID NCT03739853

Completed Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested whether starting stronger medications early helps people with moderate to severe psoriatic arthritis more than the usual step-up approach. 192 adults were randomly assigned to standard care, early combination disease-modifying drugs, or early TNF inhibitors. The study measured disease activity using a composite score to see which strategy works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methotrexate, Sulfasalazine, Leflunomide, Adalimumab
What this could lead to: If successful, this could show that starting stronger drugs earlier helps control psoriatic arthritis better than the usual step-up approach.
What could go wrong: This is a completed Phase 4 trial with 192 participants, so results are limited in size. More aggressive therapy may cause more side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS

Contacts and locations

Locations

Oxford University Hospitals NHS Trust

Oxford, Oxfordshire, OX3 7LD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.